BeStock  
Stocks › Biotechnology › TRVI

Trevi Therapeutics TRVI

US equityMarket cap rank #2705Biotechnology
$13.35 −$0.37 (-2.70%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $13.35 0.00%
Open$13.58
Prev close$13.72
Day range$13.23 – $13.90
Volume2.09M
Market cap$1.90B
P/E (TTM)–
Dividend yield–

Ownership & positioning

Who holds it, who is betting against it, and where the big money is moving

Institutional ownership111.8%+3.43 pts vs. prior quarter
Institutions holding260+5 vs. prior quarter
Insider trades (recent)38 buys / 12 sellsNet buying
Short interest11.83% of floatDays to cover 10.1 · as of 30 Oct 2026
Short-sale volume share18.2%5-day average of daily volume

Short-sale volume as % of daily volume

6%15%24%33%Oct '26Oct '26Nov '26

Large-order net flow, last 20 sessions

Net of large-order buying minus selling, in USD. Over this window: +$3.91M (9 inflow days, 11 outflow days).

Net flow by order size, last 20 sessions

+$3.9MSuper+$3,070Big+$4.7MMid+$2.4MSmall

Super/Big orders approximate institutional-size trades; Mid/Small approximate retail-size trades. Net buy minus sell value in each bucket, summed over the window.

The five largest holders on file together own 38.7% of shares outstanding.

Largest holders

  • FMR9.56%
  • New Enterprise Associates, Inc.9.28%
  • BlackRock8.62%
  • Frazier Life Sciences Management, LP6.97%
  • Vanguard Capital Management, LLC4.29%
  • Wellington Management Group3.99%
  • Vivo Capital, LLC3.57%
  • Woodline Partners LP2.86%

By investor type

  • Mutual Fund57.69%
  • VC/PE Fund29.46%
  • Hedge Fund18.70%
  • Public Company3.89%
  • Private Company0.79%
  • Individual/Insider0.70%
  • Family Office/Trust0.40%
  • Insurance Company0.33%

Reported short interest has risen from 8.88% to 11.83% of float over the last 6 biweekly reports (14 Aug 2026 to 30 Oct 2026).

Recent institutional activity

HolderTypePeriodShare changeNew stake
Assenagon Asset Management S.A. Mutual Fund 2026/Q3 +2,001,721 2.5%
BlackRock Mutual Fund 2026/Q3 +1,133,207 8.6%
FMR Mutual Fund 2026/Q3 +1,067,066 9.6%
Franklin Resources Mutual Fund 2026/Q3 +992,232 0.7%
Federated Hermes, Inc. Mutual Fund 2026/Q3 +773,744 0.5%
Vanguard Capital Management, LLC Mutual Fund 2026/Q3 +581,941 4.3%
TimesSquare Capital Management, LLC Mutual Fund 2026/Q3 +532,097 0.4%
Citigroup Inc. Public Company 2026/Q3 +411,022 0.3%
BNY Mellon Asset Management Mutual Fund 2026/Q3 +370,904 0.5%
Spinnaker Trust Family Office/Trust 2026/Q3 +342,239 0.2%
Candriam, Société En Commandite Par Actions Mutual Fund 2026/Q3 +341,885 0.9%
Nuveen Asset Management LLC Insurance Company 2026/Q3 +300,439 0.2%
FMR Mutual Fund 2026/Q3 +4,525,107 8.8%
Woodline Partners LP Hedge Fund 2026/Q3 +3,080,551 2.9%
First Light Asset Management, LLC Mutual Fund 2026/Q3 +2,097,215 1.5%

Institutional buy/sell activity by reporting period, largest moves first.

Insider transactions

DateInsiderTitleTransactionSharesPriceHeld after
14 Sep 2026 Michael Heffernan Independent Director Derivative Exercise and Sale -39,473 $15.88 6,351
2 Jun 2026 Anne VanLent Independent Director Other Derivative Acquisition +35,000 $13.45 35,000
2 Jun 2026 Dominick Colangelo Independent Director Other Derivative Acquisition +35,000 $13.45 35,000
2 Jun 2026 Edward Mathers Independent Director Other Derivative Acquisition +35,000 $13.45 35,000
2 Jun 2026 David Meeker Independent Chairperson Other Derivative Acquisition +35,000 $13.45 35,000
2 Jun 2026 Michael Heffernan Independent Director Other Derivative Acquisition +35,000 $13.45 35,000
18 Feb 2026 James Cassella Chief Development Officer Other Derivative Acquisition +215,000 $10.56 215,000
18 Feb 2026 Jennifer Good Co-Founder, CEO, President, & Director Other Derivative Acquisition +675,000 $10.56 675,000
18 Feb 2026 Thomas Sciascia Co-Founder & CSO Other Derivative Acquisition +85,000 $10.56 85,000
18 Feb 2026 Christopher Galletta Controller & Chief Accounting Officer Other Derivative Acquisition +35,000 $10.56 35,000
18 Feb 2026 Farrell Simon Chief Commercial Officer Other Derivative Acquisition +160,000 $10.56 160,000
7 Jan 2026 David Hastings Chief Financial Officer & Principal Financial Officer Other Derivative Acquisition +375,000 $11.21 375,000
1 Dec 2025 Christopher Galletta Controller & Chief Accounting Officer Derivative Exercise and Retained +4,225 $0.51 26,095
6 Oct 2025 Lisa Delfini Former Chief Financial Officer Intent to Sell (Form 144) -108,650 $9.50 –
2 Oct 2025 Lisa Delfini Former Chief Financial Officer Intent to Sell (Form 144) -40,000 $9.67 –
26 Aug 2025 Lisa Delfini Former Chief Financial Officer Intent to Sell (Form 144) -312,855 $8.09 –
10 Jun 2025 Anne VanLent Independent Director Other Derivative Acquisition +45,000 $6.25 45,000
10 Jun 2025 Dominick Colangelo Independent Director Other Derivative Acquisition +45,000 $6.25 45,000
10 Jun 2025 Edward Mathers Independent Director Other Derivative Acquisition +45,000 $6.25 45,000
10 Jun 2025 David Meeker Independent Chairperson Other Derivative Acquisition +45,000 $6.25 45,000

From Form 4/Form 144 filings. Negative share counts are disposals (sales, gifts, or shares withheld for taxes); positive are acquisitions.

Short interest, by report

Report dateShares short% of floatDays to cover
30 Oct 2026 16,855,987 11.8% 10.1
15 Oct 2026 16,007,187 11.2% 4.5
30 Sep 2026 14,639,150 10.3% 8.3
15 Sep 2026 12,070,625 8.5% 8.8
31 Aug 2026 12,012,371 8.4% 8.0
14 Aug 2026 12,657,630 8.9% 7.8

Discussion

No comments yet — be the first to weigh in on TRVI.

Sign in to join the discussion.

Scroll to Top